Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit
November 28, 2023 08:00 ET
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN)...
Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023
November 10, 2023 08:30 ET
|
Sagimet Biosciences Inc.
Combination treatment of a FASN inhibitor with semaglutide, a GLP-1 receptor agonist, improved several biomarkers associated with NASH in a mouse model and showed a significant improvement in liver...
Pen Needles Market Projected to Expand at a CAGR of 12.1% from 2022 to 2030, According to, Contrive Datum Insights
January 27, 2023 00:00 ET
|
Contrive Datum Insights Pvt Ltd
Farmington, Jan. 27, 2023 (GLOBE NEWSWIRE) -- The Global Pen Needles Market size was valued at USD 2.7 Billion in 2022 and is anticipated to expand at a compound annual growth rate (CAGR) of 12.1%...